These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37339569)

  • 1. Structure-based computational design of novel covalent binders for the treatment of sickle cell disease.
    Ogunlana AT; Boyenle ID; Ojo TO; Quadri BO; Elegbeleye OE; Ogbonna HN; Ayoola SO; Badmus IO; Manica AK; Joshua KI; Onikute OW; Anamelechi JP; Odetunde A; Falusi AG; Oyedele AK
    J Mol Graph Model; 2023 Nov; 124():108549. PubMed ID: 37339569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
    Howard J; Hemmaway CJ; Telfer P; Layton DM; Porter J; Awogbade M; Mant T; Gretler DD; Dufu K; Hutchaleelaha A; Patel M; Siu V; Dixon S; Landsman N; Tonda M; Lehrer-Graiwer J
    Blood; 2019 Apr; 133(17):1865-1875. PubMed ID: 30655275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes.
    Rutherford-Parker NJ; Campbell ST; Colby JM; Shajani-Yi Z
    Am J Clin Pathol; 2020 Oct; 154(5):627-634. PubMed ID: 32561909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An expert review of voxelotor for the treatment of hemolytic anemia in patients with sickle cell disease: 'bridging the gap between laboratory data and patient related outcomes'.
    Inusa BPD; Mnika K; Babiker S
    Expert Rev Hematol; 2023; 16(8):585-591. PubMed ID: 37329253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease.
    Hutchaleelaha A; Patel M; Washington C; Siu V; Allen E; Oksenberg D; Gretler DD; Mant T; Lehrer-Graiwer J
    Br J Clin Pharmacol; 2019 Jun; 85(6):1290-1302. PubMed ID: 30743314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
    N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-informed drug development of voxelotor in sickle cell disease: Exposure-response analysis to support dosing and confirm mechanism of action.
    Green ML; Savic RM; Tonda M; Jorga K; Washington CB
    CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):698-710. PubMed ID: 35447017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis.
    Shah N; Lipato T; Alvarez O; Delea T; Lonshteyn A; Weycker D; Nguyen A; Beaubrun A; Agodoa I
    Expert Rev Hematol; 2022 Feb; 15(2):167-173. PubMed ID: 35191358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
    Han J; Saraf SL; Gordeuk VR
    Pharmacotherapy; 2020 Jun; 40(6):525-534. PubMed ID: 32343424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voxelotor: A Novel Treatment for Sickle Cell Disease.
    Herity LB; Vaughan DM; Rodriguez LR; Lowe DK
    Ann Pharmacother; 2021 Feb; 55(2):240-245. PubMed ID: 32674605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years.
    Estepp JH; Kalpatthi R; Woods G; Trompeter S; Liem RI; Sims K; Inati A; Inusa BPD; Campbell A; Piccone C; Abboud MR; Smith-Whitley K; Dixon S; Tonda M; Washington C; Griffin NM; Brown C
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29716. PubMed ID: 35451176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voxelotor for the treatment of sickle cell disease in pediatric patients.
    Brown C; Tonda M; Abboud MR
    Expert Rev Hematol; 2022 Jun; 15(6):485-492. PubMed ID: 35671094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voxelotor for the Treatment of Sickle Cell Disease.
    Fantasia HC; Morse BL
    Nurs Womens Health; 2020 Jun; 24(3):233-237. PubMed ID: 32387142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
    Howard J; Ataga KI; Brown RC; Achebe M; Nduba V; El-Beshlawy A; Hassab H; Agodoa I; Tonda M; Gray S; Lehrer-Graiwer J; Vichinsky E
    Lancet Haematol; 2021 May; 8(5):e323-e333. PubMed ID: 33838113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of an Anti-Sickling Drug with Hemoglobin in Red Blood Cells from a Patient with Sickle Cell Anemia.
    Strader MB; Liang H; Meng F; Harper J; Ostrowski DA; Henry ER; Shet AS; Eaton WA; Thein SL; Alayash AI
    Bioconjug Chem; 2019 Mar; 30(3):568-571. PubMed ID: 30794381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking HbS Polymerization in SCD.
    Lettre G
    Cell; 2020 Mar; 180(5):819. PubMed ID: 32142671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model-informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma.
    Savic RM; Green ML; Jorga K; Zager M; Washington CB
    CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):687-697. PubMed ID: 35447014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute venous thromboembolism after initiation of voxelotor for treatment of sickle cell disease.
    Lemon N; Sterk E; Rech MA
    Am J Emerg Med; 2022 May; 55():225.e1-225.e3. PubMed ID: 34991907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient perception of voxelotor treatment benefit in sickle cell disease.
    Idowu M; Haque A; Williams EM; Sridhar A
    J Investig Med; 2022 Jun; 70(5):1316-1319. PubMed ID: 35732337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of potent DNMT1 inhibitors against sickle cell disease using structural-based virtual screening, MM-GBSA and molecular dynamics simulation-based approaches.
    Ala C; Joshi RP; Gupta P; Ramalingam S; Sankaranarayanan M
    J Biomol Struct Dyn; 2024; 42(1):261-273. PubMed ID: 37061929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.